文献速递淋巴瘤

外周T细胞淋巴瘤中循环肿瘤DNA的突变谱分析、肿瘤负荷评估、结局预测与疾病监测

Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma.
PubMed 文献 · Br J Haematol · 2023-05-03

这项前瞻性研究纳入47例初诊成熟T细胞和NK细胞淋巴瘤患者,评估血浆游离DNA(cfDNA)的突变谱检测价值,总体灵敏度73.9%、特异度99.6%。治疗前ctDNA浓度>1.9 log ng/mL者总缓解率、1年无进展生存率和总生存率均显著低于低水平者,纵向分析显示ctDNA动态与影像学缓解高度一致。

要点

  • 血浆cfDNA检测活检确认突变的总体灵敏度73.9%、特异度99.6%。
  • 仅考虑肿瘤活检中变异等位基因频率>5%的突变时,灵敏度升至81.9%。
  • 治疗前ctDNA>1.9 log ng/mL者总缓解率、1年无进展生存率和总生存率显著更低。

核心结论

  • ctDNA可能作为外周T细胞淋巴瘤突变谱分析、肿瘤负荷评估、结局预测和疾病监测的有前景工具。

研究设计与样本

  • 前瞻性研究,纳入47例初诊成熟T细胞和NK细胞淋巴瘤患者,采集血浆cfDNA。
  • 对47份cfDNA样本行靶向下一代测序,其中36例有配对肿瘤组织样本用于验证。

主要发现

  • 47份cfDNA样本中共鉴定出279个体细胞突变,涉及149个基因。
  • 血浆cfDNA发现活检确认突变的总体灵敏度为73.9%,特异度为99.6%。
  • 仅考虑肿瘤活检中变异等位基因频率>5%的突变时,灵敏度增至81.9%。
  • 治疗前ctDNA浓度和突变数量与乳酸脱氢酶、Ann Arbor分期和国际预后指数评分等肿瘤负荷指标高度相关。
  • ctDNA水平>1.9 log ng/mL者的总缓解率、1年无进展生存率和总生存率均显著低于低水平者;纵向分析显示ctDNA动态与影像学缓解高度一致。

关键数值与推荐

  • 血浆cfDNA检测活检确认突变的总体灵敏度73.9%,特异度99.6%。
  • 仅考虑肿瘤活检中变异等位基因频率>5%的突变时,灵敏度81.9%。
  • 高ctDNA水平定义为>1.9 log ng/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this prospective study, we aimed to evaluate the utility of circulating tumour DNA (ctDNA) in peripheral T-cell lymphomas (PTCLs). Plasma cell-free DNA (cfDNA) was obtained, and the mutational profile was assessed in 47 patients with newly diagnosed mature T- and NK-cell lymphoma. To validate the mutations detected in cfDNA, paired tumour tissue samples were available for 36 patients. Targeted next-generation sequencing was performed. A total of 279 somatic mutations involving 149 genes were identified in the 47 cfDNA samples. The overall sensitivity of plasma cfDNA in discovering biopsy-confirmed mutations was 73.9% with a specificity of 99.6%. When we considered only mutations with variant allele frequency >5% in the tumour biopsy, the sensitivity increased to 81.9%. Pretreatment ctDNA concentration and the number of mutations were highly correlated with tumour burden indicators including lactate dehydrogenase, Ann Arbor stage and International Prognostic Index score. Patients with high ctDNA level (>1.9 log ng/mL) had significantly lower overall response rates, inferior 1-year progression-free survival and overall survival rates than those with low level. Longitudinal analysis of ctDNA showed a strong agreement between ctDNA dynamics and the radiographic response. In conclusion, our study demonstrates that ctDNA may serve as a promising tool for mutational profiling, tumour burden assessment, outcome prediction and disease monitoring in PTCLs.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wei C, Wang W, Zhang Y, et al. Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T-cell lymphoma. Br J Haematol. 2023. PMID: 37132364. doi:10.1111/bjh.18824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。